0001193125-16-466650.txt : 20160217 0001193125-16-466650.hdr.sgml : 20160217 20160217123040 ACCESSION NUMBER: 0001193125-16-466650 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160217 DATE AS OF CHANGE: 20160217 EFFECTIVENESS DATE: 20160217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TriVascular Technologies, Inc. CENTRAL INDEX KEY: 0001432732 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-36419 FILM NUMBER: 161432260 BUSINESS ADDRESS: STREET 1: 3910 BRICKWAY BOULEVARD CITY: SANTA ROSA STATE: CA ZIP: 95403 BUSINESS PHONE: 707-543-8800 MAIL ADDRESS: STREET 1: 3910 BRICKWAY BOULEVARD CITY: SANTA ROSA STATE: CA ZIP: 95403 FORMER COMPANY: FORMER CONFORMED NAME: TV2 HOLDING Co DATE OF NAME CHANGE: 20091116 FORMER COMPANY: FORMER CONFORMED NAME: TV2 HOLDING CO DATE OF NAME CHANGE: 20080417 15-12B 1 d129246d1512b.htm 15-12B 15-12B

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File No. 001-36419

 

 

TRIVASCULAR TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

 

3910 Brickway Blvd.

Santa Rosa, CA 95403

(707) 543-8800

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.001 par value

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

 

 

Please place an x in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

   x

Rule 12g-4(a)(2)

   ¨

Rule 12h-3(b)(1)(i)

   x

Rule 12h-3(b)(1)(ii)

   ¨

Rule 15d-6

   ¨

Approximate number of holders of record as of the certification or notice date: One*

 

* On February 3, 2016, pursuant to the Agreement and Plan of Merger, dated as of October 26, 2015, by and among Endologix, Inc., a Delaware corporation (“Endologix”), its wholly owned subsidiary, Teton Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and TriVascular Technologies, Inc., a Delaware corporation (“TriVascular”), Merger Sub merged with and into TriVascular, with TriVascular being the surviving entity (the “Merger”). As a result of the Merger, TriVascular became a direct wholly owned subsidiary of Endologix.

Pursuant to the requirements of the Securities Exchange Act of 1934, TriVascular Technologies, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Dated: February 17, 2016   By:  

/s/ John McDermott

  Name:   John McDermott
  Title:   Chief Executive Officer